(S)-N-((R)-1-(naphthalen-1-yl)ethyl)pyrrolidin-3-amine | 870966-25-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: (S)-N-((R)-1-(naphthalen-1-yl)ethyl)pyrrolidin-3-amine
• 英文别名: (3S)-N-[(1R)-1-naphthalen-1-ylethyl]pyrrolidin-3-amine
• CAS: 870966-25-9
• 化学式: C₁₆H₂₀N₂
• 分子量: 240.348
• InChiKey: ZGVXBJUAKRUANW-OCCSQVGLSA-N

物化性质

• 沸点：
  389.6±35.0 °C(Predicted)
• 密度：
  1.09±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-N-((R)-1-(naphthalen-1-yl)ethyl)pyrrolidin-3-amine 在 四(三苯基膦)钯 、 三甲基溴硅烷 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 17.5h， 生成 (4-((S)-3-(((R)-1-(naphthalen-1-yl)ethyl)amino)pyrrolidin-1-yl)phenyl)phosphonic acid
  参考文献：
  名称：

  鉴定针对GI特异性给药的钙敏感受体的强效，不可吸收激动剂

  摘要：

  胃肠道营养物传感途径的调节为治疗包括糖尿病和肥胖症在内的代谢性疾病提供了一种有希望的新方法。钙敏感受体已被确定为涉及矿物质和氨基酸营养素敏感的关键受体，因此是肠内调节的诱人靶标。在本文中，我们描述了从包含3-氨基吡咯烷的模板开始的胃肠道限制钙敏感受体激动剂的优化，从而确定了GI限制激动剂19（GSK3004774）。

  DOI：

  10.1016/j.bmcl.2017.09.008
• 作为产物：
  描述：

  以78的产率得到(S)-N-((R)-1-(naphthalen-1-yl)ethyl)pyrrolidin-3-amine
  参考文献：
  名称：

  NOVEL CRYSTALLINE ARYLALKYLAMINE COMPOUND AND PROCESS FOR PRODUCING THE SAME

  摘要：

  本发明提供了新型芳基烷基胺化合物的晶体形式。具体而言，4-(3S-(1R-(1-萘基)乙基氨基)吡咯烷-1-基)苯乙酸的新晶体形式具有优异的稳定性，因此可用作药物成分。本发明还提供了生产芳基烷基胺化合物的工业优势工艺。

  公开号：

  US20170267633A1

文献信息

• Arylalkylamine compound and process for preparing the same
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：US08759387B2

  公开（公告）日：2014-06-24

  The present invention relates to an arylalkylamine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, a process for preparing the same, and use of the above-mentioned compound as an activating compound (CaSR agonist) of a Ca sensing receptor, a pharmaceutical composition containing the above-mentioned compound as an effective ingredient, etc. The symbols in the formula represent the following meanings: Ar: optionally substituted aryl or optionally substituted heteroaryl here, the cyclic portion of the heteroaryl is bicyclic heterocyclic ring in which 5- to 6-membered monocyclic heterocyclic ring containing 1 or 2 hetero atom(s) and benzene ring are fused; R1: a group selected from the group consisting of optionally substituted cyclic hydrocarbon group, and optionally substituted heterocyclic group; n: an integer of 1 to 3; X: single bonding arm, —CH2—, —CO—, —(CH2)m—CO—, —CH(R2)—CO—, —(CH2)p—Y—(C(R3)(R4))q—CO—, —NH—CO— or —N(R5)—CO—; in the above-mentioned respective definitions of the X, the bonding arm described at the left end represents a bond with R1; m is an integer of 1 to 3; p is an integer of 0 to 2; q is an integer of 0 to 2; Y: —O— or —SO2—; R2: phenyl or lower alkyl; R3, R4: each independently represents hydrogen atom or lower alkyl; R5: lower alkyl; provided that the ring portion of the group represented by R1 is neither naphthylidine nor partially saturated group thereof, and, when X is —CH2— or —CO—, R1 is not naphthyl.

  本发明涉及一种由以下式[I]表示的芳基烷基胺化合物或其药学上可接受的盐，其制备方法，以及上述化合物作为Ca感受受体的激活化合物（CaSR激动剂）的用途，以及包含上述化合物作为有效成分的制药组合物等。式中符号的含义如下：Ar：可选取取代的芳基或可选取取代的杂环芳基，其中杂环的环部分是一种5-至6-成员的单环杂环，它包含1或2个杂原子，并与苯环融合；R1：选自可选取取代的环烃基团和可选取取代的杂环基团的群；n：为1至3的整数；X：单键臂，—CH2—，—CO—，—（CH2）m—CO—，—CH（R2）—CO—，—（CH2）p—Y—（C（R3）（R4））q—CO—，—NH—CO—或—N（R5）—CO—；在上述各定义的X中，左端所述的键臂表示与R1的键合；m为1至3的整数；p为0至2的整数；q为0至2的整数；Y：—O—或—SO2—；R2：苯基或低碳基；R3，R4：各自独立地表示氢原子或低碳基；R5：低碳基；前提是由R1表示的基团的环部分既不是萘亚甲基，也不是其部分饱和基团，并且当X为—CH2—或—CO—时，R1不是萘基。
• Arylalkylamine Compound and Process for Preparing the Same
  申请人：Miyazaki Hiroshi

  公开号：US20070225296A1

  公开（公告）日：2007-09-27

  The present invention relates to an arylalkylamine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, a process for preparing the same, and use of the above-mentioned compound as an activating compound (CaSR agonist) of a Ca sensing receptor, a pharmaceutical composition containing the above-mentioned compound as an effective ingredient, etc. The symbols in the formula represent the following meanings: Ar: optionally substituted aryl or optionally substituted heteroaryl here, the cyclic portion of the heteroaryl is bicyclic heterocyclic ring in which 5- to 6-membered monocyclic heterocyclic ring containing 1 or 2 hetero atom(s) and benzene ring are fused; R 1 : a group selected from the group consisting of optionally substituted cyclic hydrocarbon group, and optionally substituted heterocyclic group; n: an integer of 1 to 3; X: single bonding arm, —CH 2 —, —CO—, —(CH 2 ) m —CO—, —CH(R 2 )—CO—, —(CH 2 ) p —Y—(C(R 3 )(R 4 )) q —CO—, —NH—CO— or —N(R 5 )—CO—; in the above-mentioned respective definitions of the X, the bonding arm described at the left end represents a bond with R 1 ; m is an integer of 1 to 3; p is an integer of 0 to 2; q is an integer of 0 to 2; Y: —O— or —SO 2 —; R 2 : phenyl or lower alkyl; R 3 , R 4 : each independently represents hydrogen atom or lower alkyl; R 5 : lower alkyl; provided that the ring portion of the group represented by R 1 is neither naphthylidine nor partially saturated group thereof, and, when X is —CH 2 — or —CO—, R 1 is not naphthyl.

  本发明涉及一种由以下公式[I]表示的芳基烷基胺化合物或其药学上可接受的盐，其制备方法，以及上述化合物作为钙感受受体的激活化合物（CaSR激动剂），以及含有上述化合物作为有效成分的制药组合物等的用途。公式中的符号表示以下含义：Ar：此处为可选取代的芳基或可选取代的杂环芳基，其中杂环的环部分是一个含有1或2个杂原子的5-至6元单环杂环，与苯环融合；R1：选自可选取代的环烃基团和可选取代的杂环基团的群；n：1至3的整数；X：单键臂、—CH2—、—CO—、—（CH2）m—CO—、—CH（R2）—CO—、—（CH2）p—Y—（C（R3）（R4））q—CO—、—NH—CO—或—N（R5）—CO—；在上述各定义的X中，左端所描述的键臂表示与R1的键；m为1至3的整数；p为0至2的整数；q为0至2的整数；Y：—O—或—SO2—；R2：苯基或低碳烷基；R3、R4：各自独立地表示氢原子或低碳烷基；R5：低碳烷基；前提是由R1表示的基团的环部分既不是萘亚甲基也不是其部分饱和基团，且当X为—CH2—或—CO—时，R1不是萘基。
• ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME
  申请人：MIYAZAKI Hiroshi

  公开号：US20100249049A1

  公开（公告）日：2010-09-30

  The present invention relates to an arylalkylamine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, a process for preparing the same, and use of the above-mentioned compound as an activating compound (CaSR agonist) of a Ca sensing receptor, a pharmaceutical composition containing the above-mentioned compound as an effective ingredient, etc. The symbols in the formula represent the following meanings: Ar: optionally substituted aryl or optionally substituted heteroaryl here, the cyclic portion of the heteroaryl is bicyclic heterocyclic ring in which 5- to 6-membered monocyclic heterocyclic ring containing 1 or 2 hetero atom(s) and benzene ring are fused; R 1 : a group selected from the group consisting of optionally substituted cyclic hydrocarbon group, and optionally substituted heterocyclic group; n: an integer of 1 to 3; X: single bonding arm, —CH 2 —, —CO—, —(CH 2 ) m —CO—, —CH(R 2 )—CO—, —(CH 2 ) p —Y—(C(R 3 )(R 4 )) q —CO—, —NH—CO— or —N(R 5 )—CO—; in the above-mentioned respective definitions of the X, the bonding arm described at the left end represents a bond with R 1 ; m is an integer of 1 to 3; p is an integer of 0 to 2; q is an integer of 0 to 2; Y: —O— or —SO 2 —; R 2 : phenyl or lower alkyl; R 3 , R 4 : each independently represents hydrogen atom or lower alkyl; R 5 : lower alkyl; provided that the ring portion of the group represented by R 1 is neither naphthylidine nor partially saturated group thereof, and, when X is —CH 2 — or —CO—, R 1 is not naphthyl.

  本发明涉及一种由下式[I]表示的芳基烷基胺化合物或其药学上可接受的盐，制备该化合物的方法，以及上述化合物作为钙感受受体（CaSR激动剂）的激活化合物、包含上述化合物作为有效成分的药物组合物等的用途。式中符号表示以下含义：Ar：可选取的取代芳基或可选取的取代杂环芳基，在此，所述杂环的环状部分是由1或2个杂原子的5-6元单环杂环与苯环融合而成的双环杂环；R1：选自可选取的取代环烃基团和可选取的取代杂环基团的群；n：为1至3的整数；X：单键连接臂，-CH2-，-CO-，-(CH2)m-CO-，-CH(R2)-CO-，-(CH2)p-Y-(C(R3)(R4))q-CO-，-NH-CO-或-N(R5)-CO-；在上述X的各自定义中，左端所述连接臂表示与R1的键合；m为1至3的整数；p为0至2的整数；q为0至2的整数；Y：-O-或-SO2-；R2：苯基或低碳烷基；R3，R4：各自独立地表示氢原子或低碳烷基；R5：低碳烷基；所述R1表示的基的环部分既不是萘亚甲基基团，也不是其部分饱和基团，当X为-CH2-或-CO-时，R1不是萘基。
• NOVEL CRYSTALLINE ARYLALKYLAMINE COMPOUND AND METHOD FOR PRODUCING SAME
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP3042893A1

  公开（公告）日：2016-07-13

  The present invention provides novel crystal forms of arylalkylamine compounds. Specifically, the novel crystal forms of 4-(3S-(1R-(1-naphthyl)ethylamino)pyrrolidin-1-yl)phenylacetic acid have excellent stability and therefore are useful as pharmaceutical ingredients. The present invention also provides industrially advantageous processes for producing the arylalkylamine compounds.

  本发明提供了芳基烷基胺化合物的新型晶体形式。具体来说，新型晶体形式包括 4-(3S-(1R-(1-萘基)乙氨基)吡咯烷-1-基)苯乙酸的新型晶体具有极佳的稳定性，因此可用作药物成分。本发明还提供了具有工业优势的芳基烷基胺化合物生产工艺。
• ARYLALKYLAMINES AND PROCESS FOR PRODUCTION THEREOF
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP1757582B1

  公开（公告）日：2015-12-30